Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,067 recruiting studies in this area right now.
By phase
- Not applicable3,005
- Phase 21,060
- Phase 1794
- Phase 1/Phase 2441
- Phase 3435
- Phase 4233
- Phase 2/Phase 399
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma328
- Asthma194
- Lymphoma179
- Type 1 Diabetes132
- Rheumatoid Arthritis131
- Atopic Dermatitis122
- Systemic Lupus Erythematosus121
- Acute Lymphoblastic Leukemia118
- HIV Infections105
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases79
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center49
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California498
- Maryland198
- Alabama178
- Florida151
- Arizona150
- Massachusetts118
- New York114
- Texas112
- Illinois84
- Colorado81
Recruiting studies6,067 total
- NCT04959175RecruitingPhase 1/Phase 2
Lower-dose transplant drug for older or frail patients with blood cancer
This study tests whether a lower dose of a drug used after bone marrow transplant can reduce side effects while still preventing graft-versus-host disease (a condition where donor cells attack the patient's body). It is for older patients or those who are not healthy enough for a standard, stronger conditioning regimen.
Bethesda, MarylandAges 12–85 - NCT04973605RecruitingPhase 1/Phase 2
Sonrotoclax with steroid and other drugs for multiple myeloma
This early-phase study tests sonrotoclax (a cancer medicine) in people with multiple myeloma that has come back or not responded to prior treatment. It also studies different combinations with dexamethasone plus other standard medicines, aiming to shrink tumors and improve control of the disease.
Birmingham, AlabamaAges 18 years+ - NCT04993690RecruitingPhase 1
Oral LP-168 for relapsed or hard-to-treat B-cell lymphoma
This Phase 1 study tests whether an oral medicine called LP-168 can be given safely and possibly work against lymphoma that has come back or is not responding to standard treatment. It’s mainly looking for safety, but your results could help determine whether the drug should be studied further.
Beijing, Beijing MunicipalityAges 18–80 - NCT04951622RecruitingPhase 3
Testing nipocalimab for adults with generalized myasthenia gravis
This Phase 3 study tests nipocalimab, a medication given by infusion (and in some groups by injections under the skin), to improve symptoms in adults with generalized myasthenia gravis (MG). It may help reduce weakness in daily activities, especially if you meet specific symptom and safety criteria.
Paradise Valley, ArizonaAges 18 years+ - NCT04988555RecruitingPhase 1/Phase 2
Study of an investigational drug for high-risk acute leukemia
This Phase 1/2 study tests enzomenib (DSP-5336) in people with relapsed or hard-to-treat acute leukemia (and, in some places, certain other blood cancers). The goal is to see how the drug works and how safe it is, especially for leukemia cases with specific genetic changes (KMT2A/MLL or NPM1).
Newport Beach, CaliforniaAges 12 years+ - NCT04996875RecruitingPhase 2
Bezuclastinib for advanced mast cell disease
This Phase 2 study tests bezuclastinib, a targeted medicine, in people with advanced systemic mastocytosis (including certain advanced forms with blood cancers). It aims to shrink measurable disease and improve symptoms, while helping people who may also need treatment for an associated blood cancer.
Birmingham, AlabamaAges 18 years+ - NCT04929236RecruitingPhase 3
Testing different PANZYGA doses for children with CIDP
This Phase 3 study compares different dose schedules of PANZYGA (immune-globulin) in children with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). It aims to find a dosing plan that is both safe and effective for improving symptoms and function.
Birmingham, AlabamaAges 2–17 - NCT04933721Enrolling by invitationPhase 3
Continue berotralstat for people with hereditary angioedema
This study lets people who were already taking berotralstat through earlier BioCryst studies keep the treatment going. It looks at safety and ongoing benefit for preventing hereditary angioedema attacks.
OttawaAges 2 years+ - NCT04976322Enrolling by invitationPhase 3
Long-term lupus treatment safety study with dapirolizumab
This Phase 3 study tests whether dapirolizumab pegol is safe and tolerable for people with systemic lupus erythematosus (SLE) when taken long-term. You may be offered a chance to stay on this medicine if the study team thinks you could benefit.
Birmingham, AlabamaAges 16 years+ - NCT03900221Recruiting
Pregnancy monitoring registry for multiple sclerosis in France
This study follows people who are pregnant and have multiple sclerosis (or related conditions) to better understand what happens during pregnancy. It does not appear to test a new treatment; it mainly collects health and pregnancy information.
AmiensAges Any age - NCT04963777Recruiting
Prebiotics for gut health in young people with type 1 diabetes
This trial studies whether taking prebiotics can change gut bacteria (gut microbiome) in people with type 1 diabetes. The goal is to see if these gut changes are linked to better health or diabetes-related outcomes.
Calgary, AlbertaAges 7 years+ - NCT04986293Recruiting
CPAP or BiPAP to reduce motion during radiation
This study tests whether using a breathing machine (CPAP or BiPAP) can help keep you still during radiation treatment. This may improve how accurately radiation is delivered for certain cancers treated with curative intent.
Groningen, Provincie GroningenAges 18 years+ - NCT04930653RecruitingPhase 2
Photopheresis plus mogamulizumab for advanced skin lymphoma
This Phase 2 trial tests whether a combination of photopheresis and the drug mogamulizumab can improve outcomes in adults with advanced mycosis fungoides or Sézary syndrome, which are types of skin T-cell lymphoma. It may help by targeting lymphoma cells in the skin and immune system.
Scottsdale, ArizonaAges 18 years+ - NCT04978948Recruiting
Study of a blood protein level in autoimmune disease
This study looks at how a specific protein on cell surfaces (called STIM1) appears in people with autoimmune diseases. The goal is to understand what affects this protein and how it may relate to autoimmune illness.
Brest, BrestAges 18–99 - NCT04989621RecruitingPhase 2
Orelabrutinib plus rituximab for relapsed follicular lymphoma
This Phase 2 study tests whether orelabrutinib combined with rituximab, followed by orelabrutinib alone for a while, can control follicular lymphoma that has come back or did not respond. It may help shrink tumors and keep the disease from worsening after initial response.
Guangzhou, GuangdongAges 18 years+ - NCT04988256Enrolling by invitationEarly Phase 1
Test cyclosporine versus steroids for DRESS skin reaction
This trial compares two medicines—cyclosporine and steroid treatment—for a rare, serious drug reaction called DRESS. It aims to see which treatment controls the illness more safely and effectively.
Los Angeles, CaliforniaAges 18 years+ - NCT04935684RecruitingPhase 2
Fecal transplant after bone marrow transplant to improve gut health
This Phase 2 study tests whether a fecal microbiota transplant (a processed transplant of gut bacteria) after an allogeneic bone marrow transplant is safe and helpful. Participants may benefit by improving recovery in the gut microbiome during the post-transplant period.
AmiensAges 18 years+ - NCT04931160Recruiting
Study for suspected Sjögren’s disease diagnosis
This study follows people who may have Sjögren’s disease to better understand how to diagnose it. If you have symptoms like dry eyes or dry mouth, this could help researchers confirm the diagnosis and learn what tests best explain it.
BrestAges 18 years+ - NCT04996706Enrolling by invitation
Studying lymphoma prognosis and survivorship in newly diagnosed patients
This study collects health information from people recently diagnosed with lymphoma to learn more about how the disease progresses and how to improve long-term well-being. It does not test a new treatment but helps researchers better understand what affects survival and quality of life.
Scottsdale, ArizonaAges 18 years+ - NCT04933851RecruitingPhase 2
Support for emotional distress in adults with type 1 diabetes
This study tests an emotional support program to help people with type 1 diabetes who feel significant diabetes-related distress. It may improve how you cope and support better diabetes outcomes.
San Diego, CaliforniaAges 18 years+ - NCT04998669RecruitingPhase 2
Loncastuximab plus rituximab for relapsed follicular lymphoma
This Phase 2 study tests whether loncastuximab, combined with rituximab, can shrink and control follicular lymphoma that has come back or not responded to prior treatment. It may help people who still have active disease that needs treatment and meet specific scan and blood test requirements.
Fort Myers, FloridaAges 18 years+ - NCT04984772Enrolling by invitation
HIV and hepatitis B coinfection follow-up study in Europe
This study follows people who have both HIV and hepatitis B over time to better understand how the infection responds after starting treatment. Your information (and sometimes stored blood samples) helps researchers track changes from the start of therapy to about 2 years later.
Ages 16 years+ - NCT04972942RecruitingPhase 1
Immunotherapy for high-risk T-cell blood cancers after transplant
This Phase 1 study tests a targeted immune treatment given after strong pre-treatment (myeloablative chemo plus total-body radiation) before or along with an allogeneic stem cell transplant. It may help prevent the cancer from coming back in young people with high-risk T-cell ALL or certain T-cell lymphomas.
Phoeniz, ArizonaAges Up to 39 years - NCT04958122RecruitingPhase 3
Antibiotic treatment trial for early syphilis
This Phase 3 study tests whether cefixime can treat primary, secondary, or early latent syphilis. It may help by offering another effective antibiotic option, including for some people who also have HIV (if well controlled).
Los Angeles, CaliforniaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,067 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,241 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.